Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with retinal diseases that result in blindness

[Beacon Therapeutics @BeaconTx_]

We are thrilled to announce the successful closing of our $170 million Series B, led by Forbion, with contributions from Syncona, TCGX & others. This is a milestone in our journey to bring potential treatments to patients with blinding retinal diseases.
https://t.co/hFVFmKpQ0A

[Beacon Therapeutics @BeaconTx_]

Beacon was a Proud sponsor of The Foundation Fighting Blindness’s 16th Vision Walk! Thanks to the Foundation for another great year!

[Beacon Therapeutics @BeaconTx_]

Beacon Tx is proud to sponsor Black Ties & Blindfolds, an annual fundraising event hosted by @MOMS4Sight, an organization dedicated to funding sight saving research and raising awareness. Proceeds for this event goes to @FightBlindness.

[Beacon Therapeutics @BeaconTx_]

JOIN Beacon tx TOMORROW as we unite with those who have taken important steps towards a cure by participating in the FFB VisionWalk! This event has raised over $60 million to fund sight-saving research. Learn more on how to participate or donate here:
https://t.co/SXgGSaLqyB

[Beacon Therapeutics @BeaconTx_]

Our company launch has been featured in @GENbio! @AlexWestchester chatted with our CEO, David Fellows and CMO, Dr. Nadia Waheed about how Beacon was formed, as well as our plans for the future. Read here: https://t.co/m376YgV90z

[Beacon Therapeutics @BeaconTx_]

Great to see Beacon Therapeutics featured in @BioCentury! Our CEO, David Fellows and CMO, Dr. Nadia Waheed spoke to @BioBonanos to discuss what the future holds for the Company. Read here: https://t.co/0tR0NagiV6

[Beacon Therapeutics @BeaconTx_]

We are working on a range of preclinical assets targeting dry Aged-related Macular Degeneration and cone-rod dystrophy. Our CRD asset was in-licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the @UniofOxford. https://t.co/YB4P59qL6p

[Beacon Therapeutics @BeaconTx_]

Our CEO, David Fellows and CMO, Dr. Nadia Waheed spoke to @ky_lahucik at @endpts about the recent launch of #BeaconTherapeutics! Read the full article here: https://t.co/RLCnYhMOVW

[Beacon Therapeutics @BeaconTx_]

Meet the Beacon team! We are led by an experienced management team with decades of gene therapy and ophthalmic experience. David Fellows joins us as CEO, joined by Dr Nadia Waheed as CMO and Dr. Abraham Scaria as CSO. Learn more here: https://t.co/fX5oiAu9LL

[Beacon Therapeutics @BeaconTx_]

Our lead asset, AGTC-501 is a gene therapy program currently in Phase II clinical trials for the treatment of #XLRP. AGTC-501 works to correctly express the full length of the mutated gene, thereby addressing the entirety of photoreceptor damage. See here: https://t.co/YB4P59qL6p

[Beacon Therapeutics @BeaconTx_]

Beacon was launched through a £96M funding provided by @SynconaLtd, alongside additional investors including OSE, to acquire AGTC and provide capital to each of our development candidates through to value inflection points.

Find out more here: https://t.co/r73K9onTs8

[Beacon Therapeutics @BeaconTx_]

Beacon Therapeutics has officially launched!

Here at Beacon, we are pursuing the development of a new generation of #genetherapies to treat a range of rare and prevalent #retinaldiseases.